Pharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00

Pharming Group (NASDAQ:PHAR)’s share price gapped down prior to trading on Monday . The stock had previously closed at $10.00, but opened at $9.79. Pharming Group shares last traded at $9.59, with a volume of 617 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 14th.

Pharming Group Stock Performance

The stock has a market capitalization of $637.55 million, a PE ratio of -68.71 and a beta of 0.20. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62. The stock has a fifty day moving average of $10.63 and a 200-day moving average of $11.35.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.08). Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. The company had revenue of $81.20 million for the quarter, compared to analyst estimates of $71.83 million. Equities analysts anticipate that Pharming Group will post -0.02 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Orion Portfolio Solutions LLC bought a new position in shares of Pharming Group (NASDAQ:PHAR) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,715 shares of the company’s stock, valued at approximately $134,000. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.